12,372 trials
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Aggressive Non-Hodgkin Lymphoma
Primary: Number of Patients With Grades II-IV Acute GVHD — 39; 22; 3 Participants
Hepatitis C Virus (HCV)
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 100; 80.0 percentage of participants
Post-Ischemic Stroke
Primary: Proportion of Subjects Who Show at Least a 20% Improvement on the Two Minute Walk Test (2MinWT) at Week 12 — 17; 17; 23; 97 participants
HIV Infections
Primary: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm — 95; 96 Percentage of participants
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Primary: Overall Survival — 8.9; 7.6 months
Malaria · HIV Infections
Primary: Prevalence of Malaria Defined as Positive Placental Blood Smear — 5; 6 participants — p=.76
Hepatic Veno-Occlusive Disease
Primary: Survival by Day+100 Post Stem Cell Transplant or Chemotherapy — 49.9 Percentage of participants alive
Encephalitis · Japanese Encephalitis
Primary: Percentage of Participants With Japanese Encephalitis Seroprotection Following a Single Dose of JE-CV — 2.6; 100.0; 88.2; 90.0 Percentage of participants
Osteoporosis · Prostate Cancer
Primary: Freedom From Any Bone Fracture (FABF) Rate at Three Years — 98.0; 97.4 percentage of participants — p=0.95
Chronic Idiopathic Constipation
Primary: Overall Responder 9/12 Weeks — 18.6; 16.8; 19.0; 10.7 % of Overall Responder 9/12 weeks
Smallpox
Primary: To Determine the Number of Participants With Adverse Events — 134; 30 Participants
Hemophilia A
Primary: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis — 2.9; 23.3 treated bleeds per year — p=<0.0001
Dermatitis, Atopic
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 — 10.3; 37.9; 37.2…
Herpes Zoster · Herpes Zoster Vaccine
Primary: Number of Subjects With Any Episodes of Herpes Zoster (HZ) — 17; 6; 23; 169 Participants — p=<0.0001
Recurrent Melanoma · Stage IIIA Skin Melanoma · Stage IIIB Skin Melanoma
Primary: Best Response Rate (Partial Response [PR] + Complete Response [CR]) — 6; 14 Participants — p=0.035